328233-46-1

Basic information

• Product Name: cis-3'-Oxo-spiro[cyclohexane-1,1'(3'H)-furo[3,4-c]pyridine]-4-carboxylic acid
• Synonyms: CIS-3''-OXO-SPIRO[CYCLOHEXANE-1,1''(3''H)-FURO[3,4-C]PYRIDINE]-4-CARBOXYLIC ACID
• CAS NO: 328233-46-1
• Molecular Formula: C13H13NO4
• Molecular Weight: 247.249
• Mol File: 328233-46-1.mol
• Article Data: 6

Chemical Properties

• Appearance: /
• Density: 1.41
• CAS DataBase Reference: cis-3'-Oxo-spiro[cyclohexane-1,1'(3'H)-furo[3,4-c]pyridine]-4-carboxylic acid(CAS DataBase Reference)
• NIST Chemistry Reference: cis-3'-Oxo-spiro[cyclohexane-1,1'(3'H)-furo[3,4-c]pyridine]-4-carboxylic acid(328233-46-1)
• EPA Substance Registry System: cis-3'-Oxo-spiro[cyclohexane-1,1'(3'H)-furo[3,4-c]pyridine]-4-carboxylic acid(328233-46-1)

Safety Data

• Hazardous Substances Data: 328233-46-1(Hazardous Substances Data)

Usage

General Description

Cis-3'-Oxo-spiro[cyclohexane-1,1'(3'H)-furo[3,4-c]pyridine]-4-carboxylic acid is a complex chemical compound with a spiro structure that includes a cyclohexane ring and a fused furo[3,4-c]pyridine ring. It also contains a carboxylic acid functional group. cis-3'-Oxo-spiro[cyclohexane-1,1'(3'H)-furo[3,4-c]pyridine]-4-carboxylic acid may have potential pharmaceutical or medicinal applications, as the presence of the carboxylic acid group suggests it may be capable of forming salts and esters that could be used to modify its solubility and bioavailability. Its spiro structure and fused ring system also suggest potential biological activity, although further research would be needed to determine its specific properties and applications.

Upstream product

• 328233-17-6 trans-3-oxo-3H-spiro[5-aza-2-benzofuran-1,1'-cyclohexane]-4'-carbonitrile 

Downstream Products

• 1195313-68-8 trans-3-oxo-N-(3-phenyl-1H-pyrazol-5-yl)-3H-spiro[5-aza-2-benzofuran-1,1'-cyclohexane]-4'-carboxamide 
• 328232-65-1 trans-N-[5-(2-fluorophenyl)-2-pyrimidinyl]-3-oxospiro[5-azaisobenzofuran-1(3H), 1'-cyclohexane]-4'-carboxamide 
• 328232-64-0 trans-N-[5-(3-fluorophenyl)-2-pyrimidinyl]-3-oxospiro[5-azaisobenzofuran-1(3H), 1'-cyclohexane]-4'-carboxamide 
• 1192312-57-4 C₂₄H₂₁FN₄O₄ 
• 328232-69-5 C₂₄H₂₁FN₄O₄ 
• 1192312-56-3 C₂₃H₁₉FN₄O₃ 

Relevant articles and documents

Discovery of trans-N-[1-(2-fluorophenyl)-3-pyrazolyl]-3-oxospiro[6-azaisobenzofuran-1(3H),1′-cyclohexane]-4′-carboxamide, a potent and orally active neuropeptide Y Y5 receptor antagonist

A series of trans-3-oxospiro[(aza)isobenzofuran-1(3H),1′-cyclohexane]-4′-carboxamide derivatives were synthesized to identify potent NPY Y5 receptor antagonists. Of the compounds, 21j showed high Y5 binding affinity, metabolic stability and brain and cerebrospinal fluid (CSF) penetration, and low susceptibility to P-glycoprotein transporters. Oral administration of 21j significantly inhibited the Y5 agonist-induced food intake in rats with a minimum effective dose of 1 mg/kg. This compound was selected for proof-of-concept studies in human clinical trials.

Spiro compounds

Compounds of the general formula (I): wherein Ar1represents optionally substituted aryl or heteroaryl; n represents 0 or 1; T, U, V, and W each independently represent nitrogen atom or optionally substituted methine group, where at least two of them represent the said methine group; X represents methine or hydroxy substituted methine; Y represents an optionally substituted imino or oxygen atom are described and claimed. These novel spiro compounds are useful as neuropeptide Y receptor antagonists and as agents for the treatment of various kinds of cardiovascular disorders, central nervous system disorders, metabolic diseases and the like.

Spiro compounds

Spiro compounds of the general formula (I): wherein Ar1represents an optionally substituted aryl or heteroaryl; n represents 0 or 1; T, U, V and W each represent a nitrogen atom or an optionally substituted methine group, wherein at least two of which represent said methine group; X represents methine; Y represents an optionally substituted imino or oxygen atom. These novel spiro compounds exhibit neuropeptide Y receptor (NPY) antagonistic activities and are useful as agents for the treatment of various diseases related to NPY, for example, cardiovascular disorders, central nervous system disorders, metobolic diseases and the like.